Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
08/04/2022 - 04:01 PM
MENLO PARK, Calif. --(BUSINESS WIRE)--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022 .
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory College of American Pathologists-accredited . For more information, visit the Personalis websitePersonalis on LinkedIn and Twitter .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220804005031/en/
Investor Relations Contact:
Caroline Corner
investors@personalis.com
Media Contact:
Jennifer Temple
pr@personalis.com
www.personalis.com
Source: Personalis, Inc.
PSNL Rankings
#4996 Ranked by Stock Gains
PSNL Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Biotechnology, Health Technology, Health Care and Social Assistance, Medical Laboratories
Country
US
City
Menlo Park
About PSNL
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
